Clinical Report: Immunological Profiles and Clinical Features of Severe Thrombocytopenia in Neonates Diagnosed with Kasabach–Merritt Phenomenon
Overview
This study characterizes the immune profile of neonates with Kasabach-Merritt phenomenon (KMP) and identifies clinical features associated with severe thrombocytopenia. Key findings include immunological abnormalities and independent risk factors for severe thrombocytopenia.
Background
Kasabach-Merritt phenomenon (KMP) is a rare coagulopathy linked to vascular tumors, particularly in infants. Severe thrombocytopenia is a hallmark of KMP, leading to significant bleeding risks and complications. Understanding the immune profile and clinical features of KMP is crucial for effective management and treatment.
Data Highlights
Parameter
Severe Group (n=13)
Non-Severe Group (n=19)
Controls
CD3+CD4+ Proportion
Lower
Higher
Normal
CD3−CD19+ Proportion
Lower
Higher
Normal
IgG Levels
Lower
Higher
Normal
Lymphocytes Percentage (L%)
Higher
Lower
Normal
Ferritin Levels
Higher
Lower
Normal
Prolonged APTT
Yes
No
Normal
Key Findings
KMP neonates exhibited reduced CD3+CD4+ and CD3−CD19+ proportions compared to controls.
Lower IgG levels were observed in KMP neonates.
The severe KMP group had larger lesion diameters and higher levels of lymphocytes percentage, PCT, CKMB, and ferritin.
Prolonged APTT and elevated ferritin were identified as independent risk factors for severe thrombocytopenia.
Complete remission was achieved in 78.1% of KMP neonates.
Clinical Implications
Clinicians should be aware of the independent risk factors for severe thrombocytopenia, which may guide treatment decisions.
Conclusion
Neonates with KMP demonstrate significant immunological abnormalities, with specific factors associated with severe thrombocytopenia.
